title: Evaluation of red blood cell lipoperoxidation in hemodialysed patients during erythropoietin therapy supplemented or not with iron.
abstract: To investigate the effects of erythropoietin (rHuEPO) therapy supplemented or not with iron on hemolysis in hemodialysed patients (HD) we evaluated lipoperoxidation (LPO) by assaying (i) the red blood cell (RBC) antioxidant enzymatic system including superoxide dismutase (SOD), glutathione peroxidase, and catalase (Cat), (ii) RBC polyunsaturated fatty acids (PUFA) and (iii) malondialdehyde (MDA). Group 1 included 12 HD patients, group 2 had 7 HD patients with iron supplementation, group 3 comprised 12 HD patients with rHuEPO therapy and group 4 included 9 HD patients with both iron and rHuEPO therapies. No LPO was found in group 1 as regards MDA and PUFA levels. However, SOD and Cat activities were significantly elevated as compared to controls (p < 0.001). In the second group, a significant decrease in PUFA percentage was observed, particularly in 20:4(n-6) and 22:4(n-6) (the main ones involved in LPO) as compared to the other groups, whereas total MDA level was higher than that of the other groups. Similarly a decreased SOD activity was observed as compared to group 1 (p < 0.001), indicating its inactivation subsequent to an hyperproduction of reactive oxygen species through iron injection. In groups 3 and 4 no change was observed in MDA levels or PUFA percentages indicating no LPO. However, marked differences were observed in the enzymatic defense system. Particularly in group 3, SOD and Cat activities decreased when compared to group 1 (p < 0.001) whereas the association of erythropoietin and iron (group 4) increased the three enzymatic activities (p < 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Laboratoire de Biochimie Médicale A, Université de Bordeaux II, France.
authors.forename: M C
authors.initials: MC
authors.lastname: Delmas-Beauvieux
authors.forename: C
authors.initials: C
authors.lastname: Combe
authors.forename: E
authors.initials: E
authors.lastname: Peuchant
authors.forename: M A
authors.initials: MA
authors.lastname: Carbonneau
authors.forename: L
authors.initials: L
authors.lastname: Dubourg
authors.forename: V
authors.initials: V
authors.lastname: de Précigout
authors.forename: M
authors.initials: M
authors.lastname: Aparicio
authors.forename: M
authors.initials: M
authors.lastname: Clerc
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000097:blood / Q000188:drug therapy / Q000209:etiology; D002374:Catalase / Q000097:blood; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism*; D004921:Erythropoietin / Q000627:therapeutic use*; D005231:Fatty Acids, Unsaturated / Q000097:blood; D005260:Female; D005979:Glutathione Peroxidase / Q000097:blood; D006801:Humans; D007501:Iron / Q000008:administration & dosage; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects; D013482:Superoxide Dismutase / Q000097:blood; D014511:Uremia / Q000097:blood / Q000150:complications / Q000628:therapy
chemical_list: D005231:Fatty Acids, Unsaturated; D004921:Erythropoietin; D008315:Malondialdehyde; D007501:Iron; D002374:Catalase; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase